Search results
Results From The WOW.Com Content Network
Sultan Ahmed Al Jaber, CBE (Arabic: سلطان أحمد الجابر; born August 31, 1973) is an Emirati politician who is the minister of industry and advanced technology of the United Arab Emirates, [2] head of the Abu Dhabi National Oil Company (ADNOC), [3] and chairman of Masdar.
In September 2003, Al Jaber took over the management of Quinta Vale Da Gondra Hotel e SPA (Unipessoal) Lda. [13] In January 2008, Portuguese press revealed that Al Jaber is expanding his business in the Algarve and investing about €200 million to buy the Hotel Dona Filipa in Vale do Lobo, the golf course San Lourenzo in Quinta do Lago, the Hotel Penina and its 3 golf courses from Starman (a ...
The head of this year’s U.N. global climate summit urged more availability of funds to fight climate change in the Caribbean during a regional meeting Thursday in Barbados. Sultan al-Jaber, the ...
A joint venture agreement was signed in Abu Dhabi on 28 November 2007 between Tawazun Holding LLC, an investment company established by the Offset Program Bureau (OPB), Al-Jaber Trading Establishment, part of Al-Jaber Group, and Rheinmetall Munitions Systems, to set up the Al-Burkan munition factory at the Zayed Military City in Abu Dhabi.
In his first appearance at a United Nations climate meeting this year, the UAE's Minister of Industry Sultan al-Jaber said he wants the COP28 summit in Dubai to be "inclusive" and deliver a ...
Al-Jaber, who as president of COP28 facilitated the negotiations, faced criticism and scrutiny from the moment he took the position due to his oil ties. Analysis: At COP28, Sultan al-Jaber got ...
In May 2023, Mubadala agreed to buy a majority stake in a New York–based Fortress Investment Group from the SoftBank Group. The $3 billion takeover was intended to be closed in the first quarter of 2024. However, the deal that would give Mubadala 70% stakes in Fortress was being scrutinized by the U.S. national security officers.
Oprah Winfrey is leaving the board of WeightWatchers, ending a nearly decade-long stint as a director of the beleaguered company that has faced sudden competition from Ozempic.